About: Critical care management of adults with community-acquired severe respiratory viral infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Critical care management of adults with community-acquired severe respiratory viral infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Critical care management of adults with community-acquired severe respiratory viral infection
Creator	Fowler, Robert Hayden, Frederick Arabi, Yaseen
Source	Medline; PMC
abstract	With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17–53% of such patients. In addition, novel pathogens including zoonotic coronaviruses like the agents causing Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the 2019 novel coronavirus (2019 nCoV) are still being identified. Patients with severe RVIs requiring ICU care present typically with hypoxemic respiratory failure. Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza. At present, there are no antiviral therapies of proven efficacy for other severe RVIs. Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs. Evidence-based supportive care is the mainstay for management of severe respiratory viral infection. Non-invasive ventilation in patients with severe RVI causing acute hypoxemic respiratory failure and pneumonia is associated with a high likelihood of transition to invasive ventilation. Limited existing knowledge highlights the need for data regarding supportive care and adjunctive pharmacologic therapy that is specific for critically ill patients with severe RVI. There is a need for more pragmatic and efficient designs to test different therapeutics both individually and in combination. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00134-020-05943-5) contains supplementary material, which is available to authorized users.
has issue date	2020-02-10(xsd:dateTime)
bibo:doi	10.1007/s00134-020-05943-5
bibo:pmid	32040667
has license	no-cc
sha1sum (hex)	917630308f0265e62aff9b47dd1808be33922b08
schema:url	https://doi.org/10.1007/s00134-020-05943-5
resource representing a document's title	Critical care management of adults with community-acquired severe respiratory viral infection
has PubMed Central identifier	PMC7079862
has PubMed identifier	32040667
schema:publication	Intensive Care Med
resource representing a document's body	covid:917630308f0265e62aff9b47dd1808be33922b08#body_text
is schema:about of	named entity 'INCLUDING' named entity 'SPECIFIC' named entity 'CARE' named entity 'BEING' named entity 'EFFICACY' named entity 'USE OF' named entity 'HIGH' named entity 'PATHOGENS' named entity 'COMMUNITY' named entity 'MORTALITY' named entity 'SUPPORTIVE CARE' named entity 'ACQUIRED' named entity 'EVIDENCE' named entity 'REDUCED' named entity 'IS A' named entity 'IDENTIFIED' named entity 'PHARMACOLOGIC' named entity 'USE' named entity 'ZOONOTIC' named entity 'PRAGMATIC' named entity 'PLASMA' named entity 'Severe Acute Respiratory Syndrome (SARS)' named entity 'transition' named entity 'combination' named entity 'viral infections' named entity 'patients' named entity 'typically' named entity 'Non-invasive ventilation' named entity 'pharmacologic' named entity 'care' named entity 'severe' named entity 'SEVERE' named entity 'EFFECTS' named entity 'INTERVENTIONS' named entity 'LIKELIHOOD' named entity 'THERAPIES' named entity 'RESPIRATORY' covid:arg/917630308f0265e62aff9b47dd1808be33922b08 named entity 'NOVEL' named entity 'ASSOCIATED WITH' named entity 'THERAPEUTICS' named entity 'TO TEST' named entity 'ADDITION' named entity 'ACUTE HYPOXEMIC RESPIRATORY FAILURE' named entity 'COMBINATION' named entity 'EXPANDING' named entity 'ICU' named entity 'RECOMMENDED' named entity 'CORTICOSTEROIDS' named entity 'VIRAL INFECTIONS' named entity 'VIRAL PATHOGENS' named entity 'SEVERE' named entity 'TREATMENT' named entity 'TRANSITION' named entity 'RESPIRATORY VIRAL INFECTION' named entity 'ADJUNCTIVE' named entity 'BASED' named entity 'PATIENTS' named entity 'ACQUIRED' named entity 'CARE MANAGEMENT' named entity 'INVASIVE VENTILATION' named entity 'SUGGEST' named entity 'NON-INVASIVE VENTILATION' named entity 'NEED FOR' named entity 'ANTIVIRAL' named entity 'INFLUENZA' named entity 'PROVEN' named entity 'THEIR' named entity 'PNEUMONIA' named entity 'DIFFERENT' named entity 'IMMUNE' named entity 'LIKE' named entity 'LIMITED' named entity 'CAUSING' named entity 'STUDIES' named entity 'CYCLOOXYGENASE-2 INHIBITORS' named entity 'STATINS' named entity 'PRESENT' named entity 'NEURAMINIDASE INHIBITOR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software